Regional MA Lead: Inflammation & Early Pipeline (ASKAN)

Boehringer Ingelheim; Singapore; Vor Ort; SGD 230.000 - 307.000; Vollzeit

Zusammenfassung

Boehringer Ingelheim is seeking a seasoned Medical Affairs leader to steer regional strategy for inflammation and early pipeline assets across ASKAN. The role encompasses Australia, New Zealand, South Korea, Thailand, and Singapore, with emphasis on SK and AU/NZ for market size and reimbursement complexity.

The position requires MD/PhD/PharmD, 5+ years in Medical Affairs, and expertise in regulatory pathways, evidence generation, and cross-functional collaboration to ensure launch readiness and

Qualifikationen

• MD/PhD/PharmD or equivalent life sciences degree.
• Minimum 5 years in Medical Affairs, regional/multi-country experience preferred.
• Experience in inflammation/immunology or related areas is advantageous.

Aufgaben

• Act as the regional medical lead for the assigned inflammation and early pipeline assets across ASKAN.
• Lead medical strategy and execution, translating scientific insights into regional priorities and launch readiness.
• Collaborate with local medical teams, regional marketing, market access, and clinical operations to deliver an end-to-end MA launch-readiness roadmap.
• Engage with cross-functional teams to support Advisory Boards, scientific exchanges, and KEE relationship management.
• Develop regional education strategies and build deep scientific expertise on assets and disease biology.

Kenntnisse

English fluency

Cross-cultural collaboration

Strategic leadership

Ausbildung

MD/PhD/PharmD

Tools

MS Office

CRM platforms

Omnichannel tools

Jobbeschreibung

Boehringer Ingelheim is seeking a seasoned Medical Affairs leader to steer regional strategy for inflammation and early pipeline assets across ASKAN. The role encompasses Australia, New Zealand, South Korea, Thailand, and Singapore, with emphasis on SK and AU/NZ for market size and reimbursement complexity.

The position requires MD/PhD/PharmD, 5+ years in Medical Affairs, and expertise in regulatory pathways, evidence generation, and cross-functional collaboration to ensure launch readiness and